At the news
? BULLISHIMPACT 5/10 PRESS-RELEASE filed Jun 25, 2026 at 06:00 ET
DeepHealth, a wholly owned subsidiary of RadNet (RDNT), received FDA 510(k) clearances for two new breast imaging AI functionalities: BAC Assessment (identifies breast arterial calcifications as a cardiovascular risk indicator) and Mammo Dx (prior exam integration for improved cancer detection). The clearances expand the Breast Suite but no financial terms or revenue impact were disclosed.
- FDA 510(k) clearance for BAC Assessment, which automatically identifies breast arterial calcifications on standard mammograms with >90% sensitivity and >88% specificity.
- FDA 510(k) clearance for Mammo Dx (formerly ProFound Pro), which integrates prior exams to track lesions and improve cancer detection rates.
- Both functionalities are now commercially available in the U.S. and will be deployed across RadNet imaging centers.
- The clearances add to DeepHealth's Breast Suite, which already includes breast density assessment, risk assessment, and workflow tools.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access